Introduction {#s1}
============

Thrombocytopenia is a common and potentially fatal complication of chemotherapy and hematopoietic stem cell transplantation. Infusion of platelets from unrelated donors is currently the only effective treatment to prevent fatal hemorrhage. However, owing to their short storage time and increased demand, a constant shortage in the supply of platelets has become an important medical and society challenge. [@pone.0054941-Reems1] Therefore, investigation of alternative sources of platelets would be beneficial.

Hematopoietic stem cells (HSCs) can be used to generate functional megakaryocytic progenitors (MPs), megakaryocytes, and platelets on a large scale. [@pone.0054941-Decaudin1], [@pone.0054941-Chen1], [@pone.0054941-Matsunaga1] Functional MPs and platelets have successfully been produced *in vitro* from CD34^+^ hematopoietic cells from bone marrow, cord blood, and peripheral blood. [@pone.0054941-Kishore1], [@pone.0054941-NorooziAghideh1], [@pone.0054941-Bruyn1] Several studies have reported that transplantation of *in vitro* auto-producing MPs can promote platelet recovery after high-dose therapy and HSC transplantation. [@pone.0054941-Bertolini1], [@pone.0054941-Scheding1].

Umbilical cord blood is an abundant source of HSCs. [@pone.0054941-Barker1], [@pone.0054941-Barker2] Furthermore, cord blood is highly enriched in committed hematopoietic progenitor cells, including those of the megakaryocytic lineage. *In vitro* large scale production of MPs from cord blood could represent an effective platelet substitute. *In vitro* cord blood-derived MPs can be used in many non-emergency conditions, allowing platelets to be used for the emergency conditions. However, there are no reports in the literature that document the safety and efficacy of *ex vivo*--expanded cord blood-derived MPs in clinical trials.

Following high-dose chemotherapy, neutropenia and thrombocytopenia places patients at an increased risk of developing severe infectious and bleeding complications. The transplantation of *ex vivo*-generated hematopoietic progenitor cells in addition to chemotherapy represents a possible treatment for high-dose chemotherapy-induced cytopenia. Theoretically, the additional transplantation of *ex vivo* generated progenitor and post-progenitor cells might lead to the production of sufficient numbers of mature functional cells within a few days after transplantation. The feasibility and efficacy of this approach with regard to neutrophil recovery has previously been demonstrated. [@pone.0054941-Reiffers1], [@pone.0054941-McNiece1] However, potential clinical benefits of transplanted cord blood derived MPs has not yet been shown.

We successfully generated MPs from cord blood using a combination of cytokines. Based on promising results of our preclinical study, state food and drug administration (SFDA) of China approved our group to conducts a clinical trial of MP injection to patients with hematologic malignancy. We report the results of our phase 1 study of cord blood-derived MPs in 24 patients with hematological malignancy. We believe this to be the first report of MPs from cord blood in a human clinical trial.

Methods {#s2}
=======

Trial Protocols {#s2a}
---------------

The protocols for this trial are available as supporting information; see Protocol S1 and S2.

Ethics Statement {#s2b}
----------------

The study was approved by Research Ethics Committee of Peking University Cancer Hospital & Institute and by the SFDA of China. All patients provided written informed consent in accordance with the principles of the Declaration of Helsinki before enrollment. We obtained informed written consent from the next of kin, parents or guardians on the behalf of the minors/children participants involved in our study.

Patient Inclusion and Exclusion Criteria {#s2c}
----------------------------------------

Twenty-four consenting patients with advanced hematological malignancy were enrolled in this study. The target size of our study is 20--30 patients. Patients with hematological malignancy were eligible to receive MPs if they met the following criteria: 12--60 years of age; post-chemotherapy; 20≤PLT≤60 (×10^9^/L); no serious damage to liver and kidney function; written informed consent. The exclusion criteria: thrombocytopenia without cancer chemotherapy; patients with primary disease in important organs (liver, kidney), patients accompanied by the immune system disease, serious infections, mental disorders or organ transplant recipients; pregnant, breast-feeding women; patients did not sign informed consent form; infusion contraindication about injection of umbilical cord blood MPs.

Study Design {#s2d}
------------

This was a single-center, open-label, phase 1 clinical trial designed to assess the safety profile of infusion of *ex vivo*-expanded cord blood-derived MPs after chemotherapy. MPs from cord blood were infused when the platelet of patients was 20≤PLT≤60 (10^9^/L) after chemotherapy, and the toxicity was evaluated. The interval time between the cord blood MPs preparation and patient infusion was two hours. Before MP infusion, the patients was given 10 ml 10% calcium gluconate to prevent anaphylaxis. The overall infusion time was within two hours. Platelet counts were assessed at least twice per week. After treatment with cord blood-derived MPs, we conducted one-year follow-up. The study flow chart is depicted in [Figure 1](#pone-0054941-g001){ref-type="fig"}. This study was registered with <http://www.chictr.org>, number ChiCTR-TCH-09000333.

![Study flow chart.](pone.0054941.g001){#pone-0054941-g001}

In vitro Suspension Culture {#s2e}
---------------------------

After informed consent had been obtained, cord blood from healthy volunteers was collected into sterile heparinized tubes. Mononuclear cells were obtained by centrifugation on Lymphoprep density gradient. Ex vivo cultures were set up with cord blood MNCs at 3×10^6^ cells/mL in StemSpan medium supplemented with 50 ng/mL thrombopoietin (TPO) (Shenyang Sunshine Pharmaceutical Company Limited), 20 ng/mL interleukin-3 (IL-3) (Peprotech), 50 ng/mL stem cell factor (SCF) (Peprotech) and 50 ng/ml IL-6 (Peprotech) using 75 cm^2^ tissue culture flasks (Corning). At indicated time points, the cultured cells were harvested, washed, and prepared for immediate infusion.

Flow Cytometry Analysis {#s2f}
-----------------------

*Ex vivo*-generated cells were characterized by flow cytometry on day 0, 7, 10, and 14. All of the conjugated antibodies and the corresponding isotype controls were purchased from BD Pharmingen. The antibodies used were CD3, CD14, CD19, CD41, CD56, and CD61. MPs were collected and washed twice in PBS with 0.1% BSA and stained in accordance with the manufacturer's suggested concentration of conjugated antibody for 30 min at 4°C. The stained cells were then washed twice in PBS with 0.1% BSA and fixed with the wash buffer supplemented with 1% paraformaldehyde. The samples were then analyzed using a flow cytometer (Becton Dickinson). Cell populations were analyzed with the CellQuest program(Becton Dickinson). Three experiment were performed. We also analyzed the cell size and the co-staining of CD41 on the cultured MPs.

Colony Forming Unit-MK Assay {#s2g}
----------------------------

To demonstrate Colony forming unit-MK colonies, 5×10^4^ *in vitro* cultured cells were cultured with MegaCult-C media (StemCell Technologies) in the presence of 10 ng/mL recombinant human IL-3 (Peprotech), 20 ng/mL recombinant human IL-6 (Peprotech), and 50 ng/mL recombinant human TPO (Shenyang Sunshine Pharmaceutical Company Limited) according to the instruction manual. After 10--14 days, the cells were fixed, dried, and stained with an anti-CD41 specific antibody or isotype control antibody according to the manufacturer's instructions. CFU-MK colonies were defined as colonies with at least 3 megakaryocytes. Three experiment were performed.

Megakaryocytes Analysis {#s2h}
-----------------------

For morphological analysis of mature megakaryocytes in the culture, day 14 cultured cells were centrifuged using a cytospin centrifuge. Slides were then stained with Wright-Giemsa. We also analyzed the platelets generation in the day 14 culture by flow cytometry. Culture-derived platelets were enumerated as CD41^+^ events with the same scatter properties as blood platelets. Ten thousand events were counted per sample. Three experiment were performed.

End Points and Definitions {#s2i}
--------------------------

The primary end point was the safety and tolerability of the infusion of cord blood-derived MPs. Patients were monitored after the infusion of MPs for infusional toxicity and adverse events, which were evaluated according to World Health Organization (WHO) criteria. Secondary end points included platelet recovery after infusion of MPs. The ABO blood group and HLA typing of patients and paired cord blood were carried out at Department of hematology, Peking University People's Hospital, (Beijing, China).

Results {#s3}
=======

Patients and MP Characteristics {#s3a}
-------------------------------

Twenty-four patients (nine females/fifteen males) were treated between March 2009 and May 2010. The study flow chart is depicted in [Figure 1](#pone-0054941-g001){ref-type="fig"}. The median age was 37 years (range, 15--65 years), and the median weight was 68.5 kg (range, 50--92 kg). The patient group included 22 patients with non-Hodgkin's lymphoma (NHL), one patient with Hodgkin's lymphoma (HL), and one patient with multiple myeloma (MM). The median number of previous chemotherapy courses were of five (range, 1--17), and the median interval time between the last chemotherapy and MP infusion was 14 days (range, 3--91 days). Baseline characteristics are presented in [Table 1](#pone-0054941-t001){ref-type="table"}.

10.1371/journal.pone.0054941.t001

###### Patient characteristics.

![](pone.0054941.t001){#pone-0054941-t001-1}

  No    Age   Gender   Diagnosis   Time ofDiagnosis   Chemotherapycourses   LastChemotherapy   Recruitmenttime   Intervaltime   Chemotherapyregimen
  ---- ----- -------- ----------- ------------------ --------------------- ------------------ ----------------- -------------- ---------------------
  1     39      F       NHL IVA       2008-6-26                9                2009-4-7          2009-4-14           8           GEMOX+ENDOSTAR
  2     21      M       NHL IVB       2008-9-12               10                2009-5-5          2009-5-19           14          DICE+ ENDOSTAR
  3     29      M       HL IVB        1992-6-14               10                2009-6-1          2009-6-26           26               AraC
  4     56      M       NHL IVB       2009-2-16                7               2009-6-22          2009-7-10           19          DICE+ ENDOSTAR
  5     26      M       NHL IVB        2009-5-4                3                2009-7-8          2009-7-21           14                CAT
  6     62      F       MM III         2009-7-9                1               2009-7-19          2009-7-30           12                BTD
  7     47      F       NHL IVB       2009-6-23                1               2009-7-30          2009-8-7            9               R-CHOP
  8     40      M       NHL IVB       2009-8-11                3               2009-8-11          2009-8-21           11                MTX
  9     30      M       NHL IVA       2009-4-17                5               2009-8-28          2009-9-22           26               VALP
  10    65      F       NHL IVB       2004-9-16               16                2009-9-9         2009-10-16           37                FC
  11    19      F       NHL IVB       2009-7-16                5               2009-10-14        2009-10-28           15          DICE+ ENDOSTAR
  12    35      M         NHL         2009-11-4                1               2009-11-4         2009-11-12           9                VDLP
  13    27      M       NHL IVB       2009-10-29               1               2009-11-6         2009-11-20           15               VDLP
  14    45      M       NHL IVA       2008-2-26               17               2009-11-25         2009-12-7           14        AraC+ATO+Tioprinin
  15    45      M       NHL IVA       2008-5-21                9               2009-12-13        2009-12-15           3                GEMOX
  16    31      F       NHL IVA       2007-12-26              16               2009-12-14        2009-12-26           13               VDLP
  17    57      F       NHL IVB        2009-7-1                5               2009-12-12         2010-1-15           33                RFC
  18    59      F      NHL IIIB       1992-4-10               17               2010-1-14          2010-1-26           13          DICE+ ENDOSTAR
  19    48      M      NHL IIIB       2009-11-18               3               2010-1-25          2010-2-9            16                EP
  20    31      M       NHL IA        2009-12-14               4               2010-3-12          2010-3-23           12                MTX
  21    50      F       NHL IVA        2009-8-7                6               2010-1-15          2010-4-16           91                FC
  22    15      M       NHL IVA       2010-1-25                1               2010-4-10          2010-4-21           11              BFM-90
  23    32      M       NHL IVA       2009-10-12               6               2010-4-19          2010-5-9            20                MTX
  24    45      M      NHL IIIB        2007-2-1                9               2010-3-31          2010-5-24           54               R-COP

Our preclinical studies had established the method to efficiently inducing and expansing cord blood mononuclear cells (MNCs) to MPs. The in vitro producing MPs were characterized by morphological observation, flow cytometry analysis, and colony formation detection. Cell morphology changed obviously with the extension of culture time ([Figure S1A](#pone.0054941.s001){ref-type="supplementary-material"}). Flow cytometry analysis showed that the expression of CD41 (a MPs marker, [Figure S1E](#pone.0054941.s001){ref-type="supplementary-material"}) and CD61 (MPs, [Figure S1G](#pone.0054941.s001){ref-type="supplementary-material"}) was greater at day 14 than day 0 (7.9 fold and 11.6 fold), while the expression of CD3 (T cells, [Figure S1B](#pone.0054941.s001){ref-type="supplementary-material"}), CD19 (B cells, [Figure S1D](#pone.0054941.s001){ref-type="supplementary-material"}), CD56 (NK cells, [Figure S1F](#pone.0054941.s001){ref-type="supplementary-material"}) was lower at day 14 than day 0 (6.7 fold, 95 fold and 17.5 fold). And the expression of CD14 (monocytes, [Figure S1C](#pone.0054941.s001){ref-type="supplementary-material"}) was also lower at day 14 than day 0 (1.6 fold). Expansion of CFU-Mk were compared in different culture time. Ex vivo expansion achieved a 64±7 fold increase in CFU-Mk by 14 days culture ([Figure S1H](#pone.0054941.s001){ref-type="supplementary-material"}). Morphological features of day 14 cultured cells and the presence of polyploid nuclei were confirmed by microscopy ([Figure S1I](#pone.0054941.s001){ref-type="supplementary-material"}). This results showed that the *ex vivo*-generated-MPs can mature to megakaryocytes at day 14 culture. Although, the number of mature megakaryocytes were still low. And we also showed that the MKs in culture produced platelets. The platelets in culture were enumerated by flow cytometry as particles having the same scatter properties as blood platelets and expressing CD41 antigen. The number of platelets released remained relatively low with a mean of 5.5±0.9% of the total expanded population on day 14. Moreover, we analyzed the cell size and co-staining of CD41. And the results of a representative experiment was shown in [Figure S2](#pone.0054941.s002){ref-type="supplementary-material"}.

Twenty-four umbilical cord blood units identified for MP manufacture contained a median of 8.55×10^7^ MNCs (range, 1.9--29 cells) and a median of 76 mL (range 47--106 mL). The results of *ex vivo* expansion culture are summarized in [Table 2](#pone-0054941-t002){ref-type="table"}. The median expansion was 73.5-fold (range, 3-365-fold). After expansion culture, the median proportion of CD41^+^\_cells was 35% (range, 8%--77%). The dose of infused MPs for individual patients is summarized in [Table 2](#pone-0054941-t002){ref-type="table"}.

10.1371/journal.pone.0054941.t002

###### *Ex vivo* expansion: Summary of product characteristics before and after expansion.

![](pone.0054941.t002){#pone-0054941-t002-2}

  NO.              Before expansion   After expansion   Composition of Transplanted Grafts                                                                                                                                    
  --------------- ------------------ ----------------- ------------------------------------ ------------ ---------------- ----------- ----------------- -------------------- -------------- -------------- ------------------ -----------------
  1                       78                4.5                         6                        11            58.5           52             304               91.4%              113             70              8.4                4.3
  2                       54                 8                          11                       5              48            26             125               94.0%               14             61              7.9                2.0
  3                       69                24                          4                        7             264            33             871               98.7%               91             67              39.4              13.0
  4                       47                4.6                         8                        6             611            22            1344               98.0%              365             57             107.2              23.6
  5                       93                8.1                         3                        8             72.9           27             197               98.9%               81             92              7.9                2.1
  6                       82                16                          8                        7             128            22             282               99.0%               22             54              23.7               5.2
  7                      106                18                          6                        4              54            13             70                99.9%               6              60              9.0                1.2
  8                       52                4.6                         9                        17            87.4           64             559               97.1%              135             81              10.8               6.9
  9                       77                1.9                         13                       20            32.3           55             178               92.2%               7              67              4.8                2.7
  10                      62                 6                          6                        4              36             9             32                99.0%               9              57              6.3                0.6
  11                      70                 5                          12                       12            130            72             936               87.8%              156             79              16.5              11.8
  12                      77                 7                          5                        14            119            67             797               93.0%              228             67              17.8              11.9
  13                      72                10                          6                        4              20             8             16                95.0%               3              63              3.2                0.3
  14                      78                 9                          9                        12            198            77            1525               91.0%              188             70              28.3              21.8
  15                      86                10                          8                        14            310            54            1674               84.4%              209             86              36.0              19.5
  16                      99                15                          6                        7             120            23             276               93.7%               31             82              14.6               3.4
  17                      56                11                          5                        4              44            13             57                98.0%               10             78              5.6                0.7
  18                      93                 9                          5                        8             135            37             500               84.0%              111             80              16.9               6.2
  19                      89                12                          8                        13            192            58            1114               95.1%              116             66              29.1              16.9
  20                      70                20                          5                        13            380            63            2934               92.0%              293             80              47.5              29.9
  21                      72                 6                          9                        22             96            32             307               94.2%               57             50              19.2               6.1
  22                     102                29                          6                        6             132            18             238               93.9%               14             88              15.0               2.7
  23                      65                6.6                         11                       16             85            52             442               92.0%               61             78              10.9               5.7
  24                      75                5.1                         8                        11             56            48             269               90.2%               66             61              9.2                4.4
  Median(range)      76(47--106)       8.55(1.9--29)                 7(3--13)                9.5(4--22)   107.5(20--611)   35(8--77)   305.5(16--2934)   93.95%(84--99.90%)   73.5(3--365)   68.5(50--92)   14.8(3.2--107.2)   5.45(0.3--29.9)

CB, cord blood; MNC: mononuclear cells.

MP Infusion Toxicity Profile {#s3b}
----------------------------

The infusion toxicity profile is summarized in [Table 3](#pone-0054941-t003){ref-type="table"}. Severe adverse events associated with infusion of cultured cord blood-derived MPs were not observed. Two patients experienced fever (\<38°C), four patients exhibited increased transaminases, one patient experienced increased jaundice (jaundice was present prior to infusion of MPs), and one patient experienced vomiting. All conditions were resolved with standard clinical management. With regard to four patients with elevated transaminases, we recorded the transaminase changes before and after the MP infusion. The results showed that all four patients experienced increased transaminitis prior to infusion of MPs. ([Figure S3](#pone.0054941.s003){ref-type="supplementary-material"}) In the present clinical trial, we did not carry out the ABO blood group and HLA matching. However, after one year follow-up acute and chronic GVHD had not been observed among patients who received MPs infusion. The ABO blood group and HLA typing data of patients and paired cord blood were shown in [Table S1](#pone.0054941.s004){ref-type="supplementary-material"}.

10.1371/journal.pone.0054941.t003

###### Adverse reaction in MP-infusion patients.

![](pone.0054941.t003){#pone-0054941-t003-3}

  Adverse events                                    No                   Patient Number
  -------------------------------- ------------------------------------ ----------------
  **Fever**                                         2                        10, 15
  **Anaphylaxis**                                   0                          NA
  **Hemolysis**                                     0                          NA
  **Shock**                                         0                          NA
  **Embolism**                                      0                          NA
  **Hepatolienomegaly**                             0                          NA
  **Abnormal electrocardiogram**                    0                          NA
  **Transaminitis**                 4[\*](#nt102){ref-type="table-fn"}    1, 2, 7, 20
  **Abnormal renal function**                       0                          NA
  **Jaundice**                      1[†](#nt103){ref-type="table-fn"}          7
  **Vomiting**                                      1                          20
  **Diarrhea**                                      0                          NA
  **Erythra**                                       0                          NA
  **GVHD**                                          0                          NA

All four patients exhibited increased transaminitis before infusion of MPs.

Jaundice existed before infusion of MPs.

Clinical Reactions {#s3c}
------------------

The median dose of infused MPs was 14.8×10^6^ MNCs/kg body weight (range, 3.2×10^6^−107.2×10^6^), and 5.45×10^6^ CD41^+^ cells/kg body weight (range 0.3×10^6^−29.9×10^6^). Platelet recovery occurred in 17 patients with a median platelet recovery \>60×10^9^/L on day 3 (median, 1 to 16 days) and in 13 patients with a median platelet recovery \>100×10^9^/L on day 6 (median, 3 to 14 days). However, 5 patients received transfusion of one unit of platelets after infusion of MPs. In the absence of platelet transfusion, platelet recovery was prompt in 12 patients with a median platelet recovery \>60×10^9^/L on day 3 (median, 1 to 11 days), and 11 patients with a median platelet recovery \>100×10^9^/L on day 6 (median, 3 to 14 days). The summary of platelet recovery after infusion of MPs is shown in [Table 4](#pone-0054941-t004){ref-type="table"}. However, it was difficult to determine whether there is any benefit to the administration of MPs after chemotherapy without appropriate controls. And definitive results will require the completion of a randomized phase 2 clinical trial.

10.1371/journal.pone.0054941.t004

###### Platelet recovery parameters after infusion of *ex vivo*-generated cells.
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  Patient No    PLT Day 0×10^9^/L   Platelets (PLT)   Number of PLT transfusions       
  ------------ ------------------- ----------------- ---------------------------- ---- ---
  **1**                52                 13                      NA               NA   0
  **2**                57                 NA                      4                8    0
  **3**                46                 NA                      2                5    1
  **4**                49                  3                      2                6    0
  **5**                45                  4                      NA               NA   0
  **6**                37                 NA                      3                5    0
  **7**                 4                  0                      10               NA   1
  **8**                49                 NA                      10               NA   0
  **9**                53                 NA                      2                7    0
  **10**               56                 NA                      3                NA   0
  **11**               56                 NA                      1                3    0
  **12**               53                 NA                      2                5    0
  **13**               51                 NA                      11               14   0
  **14**               24                 NA                      7                14   0
  **15**               24                  2                      NA               NA   1
  **16**               63                  4                      NA               NA   1
  **17**               41                 NA                      16               NA   0
  **18**               23                 NA                      NA               NA   1
  **19**               30                 NA                      2                6    0
  **20**               46                 NA                      3                5    0
  **21**               25                 NA                      NA               NA   0
  **22**               35                 NA                      10               12   0
  **23**               44                 NA                      4                6    0
  **24**               47                 NA                      NA               NA   0

NA, not applicable.

Discussion {#s4}
==========

To our knowledge, this is the first report of the use of *ex vivo*--expanded cord blood-derived MPs in humans. We investigated the feasibility of *in vitro* expansion and transplantation of cord blood-derived MPs in 24 patients with advanced hematological malignancy. Administration of *ex vivo*-generated cell numbers up to a median of 5.45×10^6^/kg body weight was performed, with no adverse effects. Administration of cord blood-derived MPs appears to be safe and feasible for treatment of thrombocytopenia after chemotherapy.

The additional transplantation of *ex vivo*-generated cell populations containing up to a median of 14.8×10^6^ MNCs/kg (range, 3.2×10^6^−107.2×10^6^), and a median of 5.45×10^6^ CD41^+^ cells/kg (range, 0.3×10^6^−29.9×10^6^), is comparable to the number of additionally transplanted megakaryocytic in previous studies. [@pone.0054941-Bertolini1], [@pone.0054941-Scheding1] Our present study showed that there were no significant detriment to the administration of dose escalated MP. Now, many studies try to improve the efficiency of MP differentiation and expansion from stem cells. [@pone.0054941-Pineault1], [@pone.0054941-Mercher1], [@pone.0054941-PoiraultChassac1] The most recent studies also show that platelets can be efficiently produced from pluripotent stem cell *in vitro*. [@pone.0054941-Takayama1]--[@pone.0054941-Takayama2] All of these studies indicate promise for *in vitro*-produced platelet substitutes from stem cells.

Our study hadn't showed definitive efficacy of MP infusion on thrombocytopenia after chemotherapy. Other similar clinical studies have used autologous MPs or megakaryocyte infusion; however, these studies also lacked a control group, and thus cannot demonstrate the exact effect of infusion of *ex-vivo*-expanded studies. [@pone.0054941-Decaudin1], [@pone.0054941-Chen1], [@pone.0054941-Bertolini1], [@pone.0054941-Scheding1] Platelet recovery after chemotherapy can be influenced by patient condition, different chemotherapy regimens, and dosage and opportunity of infusion. Therefore, the efficacy of infusion of cord blood-derived MPs needs to be verified by larger phase 2 clinical trials.

There are limits in our present study. The efficiency of *in vitro* expansion should be improved, and platelet recovery effects need to be further explored by phase 2 study. In our study, patients had advanced hematological malignancy, and repeated chemotherapy can result in damage to the hematopoietic microenvironment, possibly influencing the effects of MP infusion.

In conclusion, this study demonstrates the safety of *ex vivo*-expanded MPs from CB infused after chemotherapy in patients with hematological malignancy. Our study also demonstrated the feasibility of manufacturing 3×10^8^ MPs from cord blood units to provide a cell dosage of 3.75×10^6^ cells/kg for an 80-kg recipient. However, definitive efficacy will require the completion of a randomized phase 2 clinical trial.

Supporting Information {#s5}
======================

###### 

**Characterization of megakaryocytic progenitors from cord blood mononuclear cells.** (A) Cell morphology of different culture time by microscope observation. Scale bars: 100 µm. Surface marker expression of CD3 (B), CD14 (C), CD19 (D), CD41 (E), CD56 (F), and CD61 (G) in expanded CB population during 14 days of culture. (H) CFU-Mk expansions after 14 days of culture. Data are shown as mean±SD from three experiments. (I) Typical morphology of mature megakaryocytes on day 14 culture was shown. Scale bars: 50 µm.

(TIF)

###### 

Click here for additional data file.

###### 

**FACS plots showed the cell size and co-staining of CD41^+^ cells at day 14 culture.** (A) and (B) showed the results of isotype IgG. (C) and (D) showed the results of CD41 expression.

(TIF)

###### 

Click here for additional data file.

###### 

**Transaminase changes of four patients before and after MPs infusion.** (A) Data of patient 1. The chemotherapy time is 2009/4/7, and the MPs infusion time is 2009/4/14. (B) Data of patient 2. The chemotherapy time is 2009/5/5, and the MPs infusion time is 2009/5/19. (C) Data of patient 7. The chemotherapy time is 2009/7/30, and the MPs infusion time is 2009/8/7. (D) Data of patient 20. The chemotherapy time is 2010/3/12, and the MPs infusion time is 2010/3/23. All the four patients had different degrees of elevated transaminases before MP treatment. Dashed lines shows the normal value of ALT and AST. ALT: alanine transarninase, AST: aspartate aminotransferase.

(TIF)

###### 

Click here for additional data file.

###### 

**ABO blood group and HLA typing data of patients and paired cord blood.**

(DOC)

###### 

Click here for additional data file.

###### 

(DOC)

###### 

Click here for additional data file.

###### 

(DOC)

###### 

Click here for additional data file.

[^1]: **Competing Interests:**The authors have declared that no competing interests exist.

[^2]: Conceived and designed the experiments: JFX HHZ DQL XN XTP. Performed the experiments: JFX XN LC YL. Analyzed the data: YHL XYX YFW WY. Wrote the paper: JFX HHZ JZ XTP. Patient enrollment: HHZ WZ WS. Quality control of cord blood: KYL XX XFW. Clinical study design: JFX HHZ DQL FY JZ XJH XTP.

[^3]: ¶ These authors are Joint Senior Authors.
